Acute Coronary Syndrome Market - Insights into Epidemiology, Emerging Therapies, and Key Players | DelveInsight | Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalC

The Acute Coronary Syndrome market size in the 7MM was around ~USD 2,670 million in 2023 and is expected to increase with a significant CAGR during the study period (2020-2034).

Therapies for Acute Coronary Syndrome, including LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and several others, are anticipated to drive growth in the Acute Coronary Syndrome market over the coming years.

DelveInsight has introduced a new report, "Acute Coronary Syndrome - Market Insights, Epidemiology, and Market Forecast 2034," which offers a comprehensive analysis of the disease, covering historical and projected epidemiology, as well as market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Acute Coronary Syndrome market report [https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Some of the key facts of the Acute Coronary Syndrome Market Report:

In 2023, the Acute Coronary Syndrome (ACS) market across the seven major markets (7MM) was valued at around USD 2.67 billion, with forecasts projecting a strong compound annual growth rate (CAGR) through 2034. The United States dominated the market, accounting for nearly 80% of the total ACS market share that year.

Clinical trial updates have also shaped the landscape:

*
April 2024: Results from the EMPACT-MI trial showed that JARDIANCE (empagliflozin) did not significantly lower the combined risk of all-cause death and heart failure-related hospitalizations in high-risk AMI patients compared with placebo.

*
February 2024: CSL reported Phase III findings from the AEGIS-II trial of CSL112 (apolipoprotein A-I [human]). While the therapy did not meet its primary endpoint of reducing major adverse cardiovascular events (MACE) within 90 days, it demonstrated good safety and tolerability. CSL confirmed it has no immediate regulatory submission plans.

*
September 2023: DalCor Pharmaceuticals announced that an interim efficacy readout of the Dal-GenE-2 trial is expected in 2026, with completion in 2027. The company also secured USD 80 million in Series D funding to advance the confirmatory study in North America under an FDA Special Protocol Assessment (SPA).

From an epidemiological perspective, the overall incidence of ACS in the 7MM was estimated at ~2.2 million cases in 2023, with the United States recording the highest number of new cases. Within the U.S., NSTEMI cases (607,300) outnumbered STEMI cases. In Europe (EU4 and the UK), ACS affected ~514,410 males and ~269,750 females, while in Japan, there were 45,700 STEMI cases and 34,500 NSTEMI cases.

A major milestone in therapy came with the FDA approval of LODOCO (colchicine) by AGEPHA Pharma, making it the first approved treatment specifically targeting residual inflammatory risk in ACS patients. By modulating inflammatory pathways, LODOCO aims to reduce the likelihood of future cardiac events.

Several companies are advancing the treatment landscape, including Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, and Abcentra.

Key therapies driving future growth in the ACS market include LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others.

Acute Coronary Syndrome Overview

Acute Coronary Syndrome (ACS) encompasses a range of conditions caused by a sudden or significant reduction in blood flow to the heart muscle, leading to tissue damage. It includes heart attacks, unstable angina, ST-Elevation Myocardial Infarction (STEMI), and Non-ST-Elevation Myocardial Infarction (NSTEMI). ACS is a subtype of Coronary Heart Disease (CHD), which remains a major global health concern, responsible for about one-third of deaths among individuals over 35. Unlike certain forms of CHD that may be asymptomatic, ACS invariably presents with clear clinical symptoms.

The condition is most often triggered by the rupture of an arterial plaque, which leads to the formation of a blood clot within a coronary artery. Portions of this clot can break away, further obstructing blood flow and precipitating ACS. In less common cases, coronary artery spasms may restrict circulation. Regardless of the cause, such blockages are highly damaging to the heart and represent a medical emergency.

Acute Coronary Syndrome Market Outlook

The management of Acute Coronary Syndrome (ACS) focuses on relieving symptoms, preventing further clot formation, restoring adequate blood flow to the heart, limiting heart muscle damage, reducing cardiac workload, and addressing or avoiding complications. Standard treatment often combines revascularization techniques, including percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), or fibrinolytic therapy, with the use of medications that target both ACS and the underlying coronary artery disease.

Discover how the Acute Coronary Syndrome market is rising in the coming years @ https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Acute Coronary Syndrome Marketed Drugs

*
LODOCO (colchicine): AGEPHA Pharma

*
REPATHA (evolocumab): Amgen

Acute Coronary Syndrome Emerging Drugs

*
Dalcetrapib (RO4607381): DalCor Pharmaceuticals and Roche

*
Dutogliptin: Recardio

Scope of the Acute Coronary Syndrome Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acute Coronary Syndrome Companies: Idorsia Pharmaceuticals, Viatris, Recardio, AstraZeneca, Faraday Pharmaceuticals, DalCor Pharmaceuticals, Roche, Jiangsu Vcare PharmaTech, CeleCor Therapeutics, Novo Nordisk, Bristol Myers Squibb, Johnson & Johnson Innovative Medicine, CellProthera, BioCardia, Kancera, Amgen, Arrowhead Pharmaceuticals, Abcentra, and others

*
Key Acute Coronary Syndrome Therapies: LODOCO (colchicine), TNKase (tenecteplase), REPATHA (evolocumab), ZONTIVITY (vorapaxar), PRALUENT (alirocumab), LOVENOX (enoxaparin sodium), Aggrastat (tirofiban), REOPRO (abciximab), and others

*
Acute Coronary Syndrome Therapeutic Assessment: Acute Coronary Syndrome current marketed and Acute Coronary Syndrome emerging therapies

*
Acute Coronary Syndrome Market Dynamics: Acute Coronary Syndrome market drivers and Acute Coronary Syndrome market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acute Coronary Syndrome Unmet Needs, KOL's views, Analyst's views, Acute Coronary Syndrome Market Access and Reimbursement

To know what's more in our Acute Coronary Syndrome report, visit https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Acute Coronary Syndrome Market Report:

*
Acute Coronary Syndrome market report covers a descriptive overview and comprehensive insight of the Acute Coronary Syndrome Epidemiology and Acute Coronary Syndrome market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Acute Coronary Syndrome market report provides insights into the current and emerging therapies.

*
The Acute Coronary Syndrome market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Acute Coronary Syndrome market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Acute Coronary Syndrome market.

Got queries? Click here to know more about the Acute Coronary Syndrome market Landscape [https://www.delveinsight.com/report-store/acute-coronary-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Acute Coronary Syndrome Patient Share (%) Overview at a Glance

5. Acute Coronary Syndrome Market Overview at a Glance

6. Acute Coronary Syndrome Disease Background and Overview

7. Acute Coronary Syndrome Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Coronary Syndrome

9. Acute Coronary Syndrome Current Treatment and Medical Practices

10. Unmet Needs

11. Acute Coronary Syndrome Emerging Therapies

12. Acute Coronary Syndrome Market Outlook

13. Country-Wise Acute Coronary Syndrome Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Acute Coronary Syndrome Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Acute Coronary Syndrome Market Outlook 2034 [https://www.delveinsight.com/sample-request/acute-coronary-syndrome-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Acute Coronary Syndrome Pipeline Insights, DelveInsight

"Acute Coronary Syndrome Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Acute Coronary Syndrome market. A detailed picture of the Acute Coronary Syndrome pipeline landscape is provided, which includes the disease overview and Acute Coronary Syndrome treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-coronary-syndrome-market-insights-into-epidemiology-emerging-therapies-and-key-players-delveinsight-idorsia-pharmaceuticals-viatris-recardio-astrazeneca-faraday-pharmaceuticals-dalc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.